Nkarta Inc

NASDAQ:NKTX   1:12:26 PM EDT
16.79
-0.44 (-2.55%)
Products, Regulatory

Nkarta Announces Updates To NKX019, NKX101 Clinical Development Programs

Published: 10/07/2021 20:06 GMT
Nkarta Inc (NKTX) - Nkarta Announces Updates to Nkx019 and Nkx101 Clinical Development Programs.
Nkarta Inc - First Patients Dosed in Phase 1 Clinical Trial Evaluating Nkx019 in Cd19+ Advanced B Cell Malignancies.
Nkarta Inc - Initial Data From Nkx019 Clinical Trial Expected in 2022.
Nkarta Inc - Initial Data From Phase 1 Clinical Trial Evaluating Nkx101 in Aml and Mds Expected in 1h 2022.